Enhancing TPP1 activity may therefore represent a dual-action therapeutic strategy that unifies lysosomal repair and α-synuclein clearance, underscoring its distinct mechanistic role and translational relevance among emerging PD DMT candidates. The gene discussed is SNCA; the disease is Parkinson disease.